EIT-RAWMATERIALS
7.9.2022 09:31:40 CEST | Business Wire | Press release
A leading innovator in science has urged European universities and higher education institutions to revolutionise their innovation activities to effectively tackle climate change. Dr. Riam Kanso, founder and CEO of Conception X, will be the keynote speaker at the INNOVEIT Stockholm: Innovation in Higher Education on 15 September. The event is coordinated and led by EIT RawMaterials, the world’s largest consortium on raw materials, funded by the European Institute of Innovation and Technology (EIT), a body of the European Union.
The registration for in-person or virtual attendance at INNOVEIT Stockholm is now open.
Reaching net-zero carbon emissions by 2050 means new innovations in technology and energy are urgently needed. These innovations will largely stem from universities and higher education institutions. The EIT Higher Education Institutions Initiative (EIT HEI) funds and supports higher education institutions in growing their research and development faculties and boosting entrepreneurship activities and synergies with industry players, many with the aim of accelerating deep tech and energy innovations coming to market (start-ups and spin-offs).
The EIT HEI Initiative is titled ‘Innovation Capacity Building for Higher Education’ and is a unique model that brings together industry/businesses with researchers and higher education. The initiative is a key objective for the EIT as part of the EIT’s new seven-year strategy for 2021-2027. The programme supports higher education institutions with expertise and coaching, access to the EIT innovation ecosystem, and funding to boost the capacity for innovation and entrepreneurship activities at European higher education institutions.
Dr. Kanso: Urgent Progress Needed for Innovation in Higher Education
Dr. Kanso’s company, Conception X, has a complementary mission to the EIT HEI Initiative. Conception X is an independent, non-profit that works closely with more than 30 universities across the UK to discover and train aspiring PhD founders from leading research labs, helping them become eligible for innovation grants, awards, and venture capital funding. Through a nine-month deep-tech venture programme, PhD students explore ways to commercialise their research while still at university – much like the EIT-Labelled Masters and PhD programmes.
Dr. Kanso says new models like this are needed to unleash Europe’s potential as a hotspot for meaningful innovation, especially with the continent’s 2050 deadline to reach net-zero emissions fast approaching.
Dr. Kanso said: “Universities and higher education institutions are built to spread knowledge that improves the world. Yet, the current system of spreading this knowledge by publishing papers can sometimes hinder progress – by the time a paper is published, the research could be three years old. We need to create models where research and innovation come together to reinforce and advance each other.”
EIT RawMaterials CEO Bernd Schäfer stressed: “Europe is at an epochal turning point, where the ambitious goals of the European Green Deal are placing more extraordinary demands on higher education than ever before. Our EIT HEI Initiative was established for this reason, to empower higher education institutions to become engines of innovation and foster sustainable growth and jobs. The initiative brings Europe’s education, research, and industry leaders together to work on strengthened innovation in higher education with the aim of solving some of the world’s biggest problems - like climate change.”
Speaking about the EIT HEI Initiative, Dr. Kanso said: “We’re working to promote knowledge and innovation and help great people excel. The more allies we have and the more connected we are, the easier it will be to achieve that. Network initiatives like the EIT HEI are crucial.’’
INNOVEIT: Stockholm - Focus on Innovation in Higher Education
This hybrid event will highlight the ongoing work of the EIT’s HEI Initiative. Discussions will focus on how the EIT HEI Initiative will connect with deep tech innovations and talents and EIT-Labelled education programmes for enhanced innovation capacity building.
All active projects selected for both the EIT HEI’s Cohort 1 (launched in July 2021) and Cohort 2 (launched in July 2022) will be present at the event. There are 23 active Cohort 1 and 26 active Cohort 2 projects in the HEI Initiative network. Cohort 1 projects will share the good practices and methodologies they have learned so far for increasing innovation capacity in European higher education institutions.
Dr. Tamer Abu-Alam is the Project Coordinator of one of EIT HEI Initiative’s funded Cohort 1 projects, CloudEARTHi, and an academic at UiT, the Artic University of Norway.
Dr. Abu-Alam says initiatives like the EIT HEI Initiative, and this event, are crucial because Europe can only be decarbonised if industry, research, and higher education work closely together.
‘’Without this coming together of stakeholders we cannot achieve a solution to the climate crisis. We are all working on the same problem - but from different perspectives. This is why the EIT HEI and the Stockholm event are so important - because everyone is brought together, everyone presents their point of view, and based on this we can innovate and work together to address this challenge.”
The CloudEARTHi project guides students on how to develop their business plan in line with the European Green Deal, and how to use big data to address gaps in their business model. Within just two months, one student has already started his own business to recycle computer components – an activity that will help to provide the EU with specific raw materials necessary for the green transition.
Dr. Tamer Abu-Alam will also take part in the panel discussion ‘EIT HEI Initiative: Innovation capacity building good practices.’
The event is an integral part of the INNOVEIT WEEKS, a series of events showcasing how EIT, Europe’s largest innovation ecosystem, offers unique opportunities to innovators and entrepreneurs, powering solutions to global challenges.
The registration for in-person or virtual attendance at INNOVEIT Stockholm is now open.
ENDS
Notes for the Editor
European Institute of Innovation and Technology (EIT)
The EIT is an EU body and an integral part of Horizon Europe, the EU Framework Programme for Research and Innovation. The Institute supports dynamic pan-European partnerships, EIT Knowledge and Innovation Communities, among leading companies, research labs, and universities. The EIT is Europe’s largest innovation ecosystem bringing together close to 3 000 partners from top business, research and education organisations across Europe in 200+ hubs. More than 3 800 students have graduated from EIT labelled master and doctoral programmes and over 100 000 have participated in EIT Community entrepreneurial trainings.
EIT HEI Initiative: Innovation Capacity Building for Higher Education
The EIT HEI Initiative: Innovation Capacity Building for Higher Education is a joint EIT Community programme led by EIT RawMaterials − one of the EIT’s Knowledge and Innovation Communities. The initiative aims to support higher education institutions with expertise and coaching, access to the EIT innovation ecosystem, and funding, enabling them to develop innovation action plans contextualised to the needs of individual higher education institutions. In July 2021, 23 projects started their activities after the EIT HEI Initiative Pilot Call. By 2027, the EIT HEI Initiative aims to support 550 higher education institutions boosting European innovation in higher education and driving the twin transition towards a more sustainable, digital and competitive Europe.
EIT RawMaterials
The objective of EIT RawMaterials is to secure a sustainable raw materials supply by driving innovation, education, and entrepreneurship across European industrial ecosystems. EIT RawMaterials provides a collaborative environment for disruptive and breakthrough innovations by connecting business with academia, research, and investment. It also invests in future generations of innovators for the raw materials sector, through initiatives ranging from the education of school students to higher qualifications for industry professionals.
The company is committed to supporting Europe’s transition towards a circular, green, and digital economy whilst strengthening its global competitiveness and securing employment. On this foundation, EIT RawMaterials has been mandated by the European Commission to lead and manage the European Raw Materials Alliance (ERMA).
EIT RawMaterials – developing raw materials into a major strength for Europe. Connecting Matters!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005543/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom